ATE358668T1 - Drogen zur behandlung maligner tumoren - Google Patents
Drogen zur behandlung maligner tumorenInfo
- Publication number
- ATE358668T1 ATE358668T1 AT00973329T AT00973329T ATE358668T1 AT E358668 T1 ATE358668 T1 AT E358668T1 AT 00973329 T AT00973329 T AT 00973329T AT 00973329 T AT00973329 T AT 00973329T AT E358668 T1 ATE358668 T1 AT E358668T1
- Authority
- AT
- Austria
- Prior art keywords
- malignant tumors
- drugs used
- treat malignant
- compounds
- formula
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 230000003211 malignant effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16140799P | 1999-10-25 | 1999-10-25 | |
| SE9903838A SE9903838D0 (sv) | 1999-10-25 | 1999-10-25 | Novel compounds |
| US21281600P | 2000-06-21 | 2000-06-21 | |
| SE0002320A SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Malignant tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE358668T1 true ATE358668T1 (de) | 2007-04-15 |
Family
ID=27484521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00973329T ATE358668T1 (de) | 1999-10-25 | 2000-10-24 | Drogen zur behandlung maligner tumoren |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1224172B1 (de) |
| JP (1) | JP3950337B2 (de) |
| KR (2) | KR100597938B1 (de) |
| AT (1) | ATE358668T1 (de) |
| AU (1) | AU775057B2 (de) |
| CA (1) | CA2386775C (de) |
| CZ (1) | CZ298534B6 (de) |
| DE (1) | DE60034240T2 (de) |
| DK (1) | DK1224172T3 (de) |
| EE (1) | EE200200207A (de) |
| ES (1) | ES2280258T3 (de) |
| HK (1) | HK1049830A1 (de) |
| HR (1) | HRP20020353A2 (de) |
| HU (1) | HU229072B1 (de) |
| IL (2) | IL148782A0 (de) |
| IS (1) | IS2750B (de) |
| NO (1) | NO323320B1 (de) |
| NZ (1) | NZ518296A (de) |
| SE (1) | SE0002320D0 (de) |
| UA (1) | UA73748C2 (de) |
| WO (1) | WO2001030758A1 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| HUE032540T2 (en) | 2004-06-24 | 2017-09-28 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
| EP2687512A1 (de) | 2005-10-19 | 2014-01-22 | Teva Pharmaceutical Industries Ltd. | Kristalle von Laquinimodnatrium und Herstellungsverfahren dafür |
| CA2635581C (en) | 2005-12-28 | 2017-02-28 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US7989473B2 (en) | 2006-06-12 | 2011-08-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| KR100916160B1 (ko) * | 2007-02-21 | 2009-09-08 | (주)바이오버드 | 약제학적 항암 조성물 |
| EP2065380A1 (de) * | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Pyridonamid-Derivate als Focal-Adhesion-Kinase (FAK) Hemmer und deren Verwendung zur Behandlung von Krebs |
| EP2234485B1 (de) | 2007-12-20 | 2013-11-13 | Teva Pharmaceutical Industries, Ltd. | Stabile laquinimod-präparate |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| UA104005C2 (ru) | 2008-09-03 | 2013-12-25 | Тева Фармасьютикл Индастриз, Лтд. | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции |
| EP2821400B1 (de) | 2009-03-20 | 2017-09-27 | Vertex Pharmaceuticals Incorporated | Verfahren zur Herstellung von CFTR-Regulatoren |
| AU2011314411B2 (en) * | 2010-10-14 | 2014-06-12 | Immunahr Ab | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AhR activators. |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| EP2537517A1 (de) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-angereichertes 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluor-methyl)phenyl]-1,2-dihydrochinolin-3-carboxamid |
| RU2692779C2 (ru) | 2012-02-27 | 2019-06-27 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтическая композиция и ее введения |
| HK1215210A1 (zh) * | 2012-11-07 | 2016-08-19 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德胺盐 |
| CA2901849A1 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| EP3041472B1 (de) * | 2014-09-23 | 2017-02-01 | Active Biotech AB | Chinolincarboxamide zur verwendung bei der behandlung von multiplem myelom |
| RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
| JP6715833B2 (ja) * | 2014-11-19 | 2020-07-01 | アクティブ バイオテック エイビー | 白血病の治療に使用するためのキノリンカルボキサミド |
| JP7223998B2 (ja) | 2017-10-13 | 2023-02-17 | 小野薬品工業株式会社 | Ａｘｌ阻害剤を有効成分として含む固形がん治療剤 |
| GEP20247646B (en) * | 2019-11-28 | 2024-07-25 | Bayer Ag | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| US20230085883A1 (en) | 2020-03-03 | 2023-03-23 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| BR112022023448A2 (pt) * | 2020-05-21 | 2023-01-31 | Stemsynergy Therapeutics Inc | Inibidores de notch e usos dos mesmos |
| KR20230133317A (ko) | 2021-01-18 | 2023-09-19 | 액티브 바이오테크 에이비 | 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염 |
| CN117295492A (zh) | 2021-05-25 | 2023-12-26 | 活跃生物技术有限公司 | 多个他喹莫德粒子及其用途 |
| CA3221689A1 (en) | 2021-07-02 | 2023-01-05 | Hans Wannman | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
| AR126963A1 (es) | 2021-09-13 | 2023-12-06 | Lilly Co Eli | Agonistas de ahr |
| TWI838849B (zh) * | 2021-09-13 | 2024-04-11 | 美商美國禮來大藥廠 | Ahr促效劑 |
| WO2023122612A2 (en) * | 2021-12-20 | 2023-06-29 | The Johns Hopkins University | Compounds for treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| GB9404378D0 (en) * | 1994-03-07 | 1994-04-20 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| GB2290786A (en) * | 1994-06-30 | 1996-01-10 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6121287A (en) * | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
-
2000
- 2000-06-21 SE SE0002320A patent/SE0002320D0/xx unknown
- 2000-10-24 ES ES00973329T patent/ES2280258T3/es not_active Expired - Lifetime
- 2000-10-24 EE EEP200200207A patent/EE200200207A/xx unknown
- 2000-10-24 JP JP2001533112A patent/JP3950337B2/ja not_active Expired - Fee Related
- 2000-10-24 DE DE60034240T patent/DE60034240T2/de not_active Expired - Lifetime
- 2000-10-24 UA UA2002032524A patent/UA73748C2/uk unknown
- 2000-10-24 HK HK03100644.7A patent/HK1049830A1/zh unknown
- 2000-10-24 DK DK00973329T patent/DK1224172T3/da active
- 2000-10-24 IL IL14878200A patent/IL148782A0/xx active IP Right Grant
- 2000-10-24 EP EP00973329A patent/EP1224172B1/de not_active Expired - Lifetime
- 2000-10-24 CZ CZ20021293A patent/CZ298534B6/cs not_active IP Right Cessation
- 2000-10-24 AT AT00973329T patent/ATE358668T1/de not_active IP Right Cessation
- 2000-10-24 KR KR1020027005077A patent/KR100597938B1/ko not_active Expired - Fee Related
- 2000-10-24 NZ NZ518296A patent/NZ518296A/xx not_active IP Right Cessation
- 2000-10-24 HR HR20020353A patent/HRP20020353A2/hr not_active Application Discontinuation
- 2000-10-24 AU AU11851/01A patent/AU775057B2/en not_active Ceased
- 2000-10-24 HU HU0203238A patent/HU229072B1/hu not_active IP Right Cessation
- 2000-10-24 CA CA002386775A patent/CA2386775C/en not_active Expired - Fee Related
- 2000-10-24 WO PCT/SE2000/002055 patent/WO2001030758A1/en not_active Ceased
- 2000-10-24 KR KR1020067008739A patent/KR100674160B1/ko not_active Expired - Fee Related
-
2002
- 2002-03-20 IL IL148782A patent/IL148782A/en not_active IP Right Cessation
- 2002-04-02 IS IS6329A patent/IS2750B/is unknown
- 2002-04-24 NO NO20021932A patent/NO323320B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE358668T1 (de) | Drogen zur behandlung maligner tumoren | |
| YU23202A (sh) | Lekovi za tretman malignih tumora | |
| DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
| DE60030741D1 (de) | Chinazoline verbindungen als heilmittel | |
| NO20024005D0 (no) | Pteridinforbindelser for behandling av psoriasis | |
| IS2114B (is) | Kínasólínafleiður til að meðhöndla æxli | |
| BR0112589A (pt) | Derivados de heteroarila e sua aplicação como medicamento | |
| SE9904505D0 (sv) | Novel compounds | |
| SE0104140D0 (sv) | Novel Compounds | |
| ATE408601T1 (de) | Fredericamycin-derivate | |
| PL367682A1 (en) | Dolastatin 10 derivatives | |
| BR0309355A (pt) | 2-(2,6-diclorofenil)-diarilimidazóis | |
| MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| ATE233754T1 (de) | Diphenyl-piperidin derivate | |
| DE60301339D1 (de) | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen | |
| BR0112807A (pt) | Derivados de indol e sua aplicação como medicamento | |
| MXPA04005809A (es) | Inhibidores de proteinas quinasas. | |
| DE602004021363D1 (de) | Imidazotriazin verbindungen zur behandlung von krebserkrankungen | |
| SE9902551D0 (sv) | Novel compounds | |
| DE60123117D1 (de) | Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs | |
| AU6826700A (en) | Ceramide analogs, process for their preparation and their use as antitumor agents | |
| BR0116123A (pt) | Carbazóis antitumorais | |
| CY1106576T1 (el) | Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας | |
| SE0004827D0 (sv) | Therapeutic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |